Our target price of NT$730 is based on 15x forward earnings. 15x is at the higher end of historical trading range since 2014, which we think is justified as the company has recovered from its earnings trough in 2Q17 and has started to bear fruit from BU reorganization with improving product offerings. We choose a P/E-based valuation methodology as the market is likely to focus on the company's earnings outlook while the industry consolidates.
|